학술논문

PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)
Document Type
Abstract
Author
Source
In Value in Health 2006 9(6):A282-A283
Subject
Contributed Poster Presentations
Language
ISSN
1098-3015